I’ve been frustrated by the tweets I’ve seen of this as a Canadian. Because the facts are being misrepresented.

We’re not under some sort of major persecution. That’s not what this is. A thread. 1/8

X : Do you think cloud will decentralise?
Me : Already has - started with regions and AZs and is now rapidly expanding into outpost, greengrass, EKS anwhere.
X : No, I mean many providers.
Me : There are two forms of decentralisation - provision and control (i.e. authorities) ...

... what is happening is decentralisation of provision (i.e. cloud everywhere, at the edge) but under centralised authorities (Amazon, Alibaba, MSFT, Google etc).
X : What about decentralisation of control?
Me : Many companies working to a common standard ...

... that was the dream of OpenStack but they blew that on day one creating a collective prisoner dilemma. They are trying to recorrect this with K8s but the cloud has moved on, higher up the stack ...

... so, the idea of a marketplace of many different companies each having authority is ... wishful thinking by past vendors and clients they've hoodwinked. Maybe in 15-20 years we will get another go ... open source is a long game ...

... more likely is many points of provision i.e. companies offering EKS anywhere on a utility basis but under centralised authority e.g. AWS.

So, yes, the cloud is going to edge, has been for sometime but it'll be AWS / Alibaba / MSFT cloud that is everywhere.

#SuvenLife – Niche R&D play..very high risk and very high reward…key is right allocation…

Jazz Pharma was quoting around $0.5 in 2009, today its $150 and Mcap of $8.5 Bn on Nasdaq..almost 300x in 11 years. 80% of its total sales ($2.1 Bn) come from single drug Xyrem.

Axovant Lifescience, bought Alzheimer molecule from GSK, repackaged it and done phase-3 trials. Before starting the trials, the valuation was $2 Bn, just before announcing the data, it rose to $3 Bn. One of the leading broker put the target of $12 Bn if the trials succeeded..

but it failed in phase-3 trials. Current Mcap is $120 Mn…

This is R&D for New Chemical Entity (NCE)…very high risk and very high reward…

Brain-related illnesses, also known as CNS diseases, afflict more than 2 billion people worldwide. Diseases of the brain and mind range

from Alzheimer’s, dementia, epilepsy, migraine, multiple sclerosis, neuro infections, Parkinson’s, psychosis, schizophrenia and stroke to brain injuries and various mental disorders. The global market or CNS therapeutics is projected to reach $137.7 billion by 2025.

#SuvenLife has 1 lead molecule SUVN-G3031 in phase-2 trials which is similar to Xyrem but superior features, 3 molecules completed phase-1 trials and starting phase-2 trials and 11 molecules in pre-clinical trials. All are related to CNS which is growing and uncluttered market

With Myanmar, it seems that some are raising questions about the efficacy of sanctions and concerns about unintended consequences. It’s time for a “Myth and Realities” guide. THREAD. #WhatsHappeningInMyanmar

Myth: Human rights groups are calling for blanket sanctions on Myanmar.
 
Reality: This is false. Most human rights groups are calling for targeted measures directed solely at the military of Myanmar and companies it owns and which give revenue directly to it.

We are talking about the conglomerates and corporations that control the country’s natural resources, including the concessions for extractive sectors (oil and gas, timber, and mining of gemstones, jade, and valuable metals).

We’re calling on governments to focus on revenues and block transactions or seize government or state assets only where there is credible information that the military or its leaders are looting or acquiring state revenues or redirecting it to them.

Myth: Even if tailored narrowly, targeted sanctions will have major negative impacts on the people of Myanmar.
 
Reality: There are all kinds of ways to prevent unintended consequences on the broader Myanmar economy.